Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.61 |
| ▸ | CCND1 | P24385 | 17/20 | 0.61 |
| ▸ | CCND2 | P30279 | 14/20 | 0.61 |
| ▸ | CCND3 | P30281 | 14/20 | 0.61 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.51 |
| ▸ | CDK2 | P24941 | 4/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828452 | 0.98 | CDK4 (0.58) | CDK4CCND1CCND2CCND3CDK6 | |
| SCHEMBL31073096 | 0.91 | CDK4 (0.73) | CDK4CCND1CCND2CCND3CDK6 | |
| SCHEMBL19766669 | 0.91 | CDK4 (0.73) | CDK4CCND1CCND2CCND3CDK6 | |
| SCHEMBL29615455 | 0.88 | CDK4 (0.75) | CDK4CCND1CCND2CCND3CDK6 | |
| SCHEMBL2074567 | 0.88 | CDK4 (0.75) | CDK4CCND1CCND2CCND3CDK6 | |
| SCHEMBL6222979 | 0.88 | CDK4 (0.57) | CDK4CCND1CCND2CCND3CDK6 | |
| SCHEMBL17311352 | 0.87 | CDK4 (0.63) | CDK4CCND1CCND2CCND3CDK6 | |
| SCHEMBL20448709 | 0.87 | CDK4 (0.60) | CDK4CCND1CCND2CCND3CDK6 | |
| SCHEMBL28050687 | 0.86 | CDK4 (0.58) | CDK4CCND1CCND2CCND3CDK6 | |
| SCHEMBL16248285 | 0.84 | CDK4 (0.57) | CDK4CCND1CCND2CCND3CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357922-B1 | 2-((5-(1-(3-(METHYLSULFONYL)PROPYL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AND RELATED COMPOUNDS AS CDK4 INHIBITORS FOR TREATING TUMORS | GUANGZHOU BEBETTER MEDICINE TECH CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| EP-3357922-B1 | 2-((5-(1-(3-(METHYLSULFONYL)PROPYL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AND RELATED COMPOUNDS AS CDK4 INHIBITORS FOR TREATING TUMORS | GUANGZHOU BEBETTER MEDICINE TECH CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-10183941-B2 | Pyrimidine or pyridopyridone compound and application thereof | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2019-01-22 | — | — | US | disclosed |
| US-20180297995-A1 | PYRIMIDINE OR PYRIDOPYRIDONE COMPOUND AND APPLICATION THEREOF | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2018-10-18 | — | — | US | disclosed |
| EP-3357922-A1 | PYRIMIDINE OR PYRIDOPYRIDONE COMPOUND AND APPLICATION THEREOF | Guangzhou Bebetter Medicine Technology Co., Ltd. (CN) | 2018-08-08 | — | — | EP | disclosed |
| CN-105130986-B | Pyrimidine or pyridopyridine ketone compounds and its application | 广州科擎新药开发有限公司 | 2017-07-18 | — | — | CN | disclosed |
| CN-105130986-A | Pyrimidine or pyridino-pyridone compound and application thereof | GUANGZHOU KEQIN NEW MEDICINE DEV CO LTD | 2015-12-09 | — | — | CN | disclosed |
| WO-2014183520-A1 | THIOPHENE MIAZINES DERIVATE, PREPARATION METHOD THEREFOR, AND MEDICAL APPLICATION THEREOF | 上海恒瑞医药有限公司 (CN) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183941-B2 | Pyrimidine or pyridopyridone compound and application thereof | CDK6, CDK4, CDK2 | CDK4 2/4885CCND1 23/4885CCND2 36/4885 |
| US-20180297995-A1 | PYRIMIDINE OR PYRIDOPYRIDONE COMPOUND AND APPLICATION THEREOF | CDK6, CDK4, CDK2 | CDK4 2/4885CCND1 23/4885CCND2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.